Why breast cancer survivors don’t take their medication, and what can be done
Why breast cancer survivors don’t take their medication, and what can be done For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for…
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer Roche announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy,…
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that…
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will…
Sanofi announces changes to its Executive Committee
Sanofi announces changes to its Executive Committee Houman, Madeleine and Emmanuel will report to Sanofi’s CEO, Paul Hudson, and will be based in Paris, France. Brian, also reporting to Paul…
Bayer to invest EUR 220 million in new R&D facility at its Monheim site
Bayer to invest EUR 220 million in new R&D facility at its Monheim site Bayer significantly strengthens its commitment to innovation in regenerative agriculture with a EUR 220 million investment in research…
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA Plus LENVIMA® in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Merck…
European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy
European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved the…
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9,…
Sandoz receives FDA approval for Tyruko first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Sandoz receives FDA approval for Tyruko first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis Sandoz, a global leader in generic and biosimilar medicines, today announced that the…
Oman Health Exhibition and Conference 2023: Pioneering Healthcare
Oman Health Exhibition and Conference 2023: Pioneering Healthcare In alignment with the Oman Vision 2040 strategy that identifies thehealthcare sector as a pivotal industry for progression, the Oman Health Exhibition…
Lilly’s Retevmo®Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Lilly’s Retevmo®Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo…